The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer

The management of localized prostate cancer is based on stage, grade, PSA, and subjective assessment of comorbidity and life expectancy. Over the last 15 y, stage migration and the improved use of Gleason sum, PSA and TNM staging have led to many treatment options for patients with newly diagnosed localized prostate cancer. At the same time, advances in treatment techniques have helped decrease the long-term complications of surgery and radiotherapy. However, the importance of age and comorbidity, in survival outcomes and treatment decision-making has been largely overlooked. Currently, stage, grade, and PSA are the only quantifiable variables consistently used in research and treatment decision-making. Comorbidity and life expectancy have remained largely subjective variables. Increasing longevity and a rapidly aging population have made age and comorbidity increasingly important factors in clinical research and treatment decision-making. This article reviews the importance of age and comorbidity on treatment decisions and survival outcomes in prostate cancer, as well as their use as objectively quantifiable variables. Examples from the general oncology literature are given. The overview also examines validated comorbidity indices and advocates the use of the Charlson Comorbidity Index (CCI) in research outcomes and treatment decision-making in prostate cancer. Several clinical vignettes are provided to demonstrate the potential clinical utility of the CCI as applied to prostate cancer.

[1]  Zuo-Feng Zhang,et al.  Prostate adenocarcinoma in men younger than 50 years. A retrospective review of 151 patients , 1994, Cancer.

[2]  G. Murphy,et al.  The national cancer data base report on race, age, and region variations in prostate cancer treatment , 1997, Cancer.

[3]  K. Domen,et al.  Comorbidity measures for stroke outcome research: a preliminary study. , 1997, Archives of physical medicine and rehabilitation.

[4]  J. Fowler,et al.  Original Articles: Prostate Cancer: Experience With Radical Prostatectomy and Radiation Therapy for Localized Prostate Cancer at a Veterans Affairs Medical Center , 1995 .

[5]  F. Marshall,et al.  Risk factors for urinary incontinence after radical prostatectomy. , 1996, The Journal of urology.

[6]  F. R. Watson,et al.  A comparison by age of death rates due to prostate cancer alone. , 1968, The Journal of urology.

[7]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[8]  J. Kirkpatrick.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. , 1998, Journal of insurance medicine.

[9]  A. D'Amico,et al.  Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. , 1997, International journal of radiation oncology, biology, physics.

[10]  M. Wilén,et al.  Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. , 1988, JAMA.

[11]  P. Rochon,et al.  Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. A prospective comparison of three comorbidity indices. , 1996, Medical care.

[12]  L. Bouter,et al.  How to measure comorbidity. a critical review of available methods. , 2003, Journal of clinical epidemiology.

[13]  M. Janssen-Heijnen,et al.  The independent prognostic value of comorbidity among men aged < 75 years with localized prostate cancer: a population‐based study , 2001, BJU international.

[14]  A. Chang,et al.  Aging and insulin secretion. , 2003, American journal of physiology. Endocrinology and metabolism.

[15]  J. V. van Meerbeeck,et al.  Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer. , 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[16]  G. Lyman,et al.  Comorbidity and functional status are independent in older cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Walter,et al.  Cancer screening in elderly patients: a framework for individualized decision making. , 2001, JAMA.

[18]  J. Brisson,et al.  Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women , 1999, Cancer.

[19]  S. Skoog,et al.  Ectopic vas deferens, imperforate anus and hypospadias: a new triad. , 1989, The Journal of urology.

[20]  C. Newschaffer,et al.  Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients. , 1998, The journals of gerontology. Series A, Biological sciences and medical sciences.

[21]  J. Goodwin,et al.  Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A W Partin,et al.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.

[23]  R. Yancik,et al.  Research recommendations for radiation therapy in older cancer patients. Report from the National Institute on Aging, National Cancer Institute, and American College of Radiology Workshop: radiation therapy and cancer in older persons. , 1999, International journal of radiation oncology, biology, physics.

[24]  H. Olsson,et al.  Clinical Course of Early Onset Prostate Cancer with Special Reference to Family History as a Prognostic Factor , 1998, European Urology.

[25]  J. Moul,et al.  Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research. , 2002, Radiology.

[26]  M. Latorre,et al.  Perioperative complications, comorbidities, and survival in oral or oropharyngeal cancer. , 2003, Archives of otolaryngology--head & neck surgery.

[27]  J. Högel,et al.  The impact of comorbidity on the overall survival and the cause of death in patients after colorectal cancer resection , 2002, Langenbeck’s Archives of Surgery.

[28]  W. Satariano,et al.  Cause of death in men diagnosed with prostate carcinoma , 1998, Cancer.

[29]  P. Walsh,et al.  Pathological stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate. , 1989, The Journal of urology.

[30]  M. Extermann,et al.  Measuring comorbidity in older cancer patients. , 2000, European journal of cancer.

[31]  A. Renshaw,et al.  Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma , 2003, Cancer.

[32]  S. Pagni,et al.  Pulmonary resection for malignancy in the elderly: is age still a risk factor? , 1998, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[33]  A W Partin,et al.  Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. , 2001, The Journal of urology.

[34]  John T. Wei,et al.  The impact of co-morbid disease on cancer control and survival following radical cystectomy. , 2003, The Journal of urology.

[35]  J. Fowler,et al.  Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. , 1996, The Journal of urology.

[36]  R. Yancik.  Cancer burden in the aged , 1997, Cancer.

[37]  J. Moul,et al.  Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research. , 2003, International journal of radiation oncology, biology, physics.

[38]  R. Weichselbaum,et al.  Potency probability following conformal megavoltage radiotherapy using conventional doses for localized prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[39]  A. Dmitrienko,et al.  A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. , 1999, Medical care.

[40]  E. Bergstralh,et al.  Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. , 2002, Journal of Urology.

[41]  C. Ruggiero,et al.  Results of surgical resection in patients over the age of 70 years with non small-cell lung cancer. , 1997, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[42]  C. Newschaffer,et al.  Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. , 2000, Journal of the National Cancer Institute.

[43]  D. Johnson,et al.  Prostatic adenocarcinoma occurring in men under 50 years of age , 1972, Journal of surgical oncology.

[44]  S. Arver,et al.  Factors associated with waning sexual function among elderly men and prostate cancer patients. , 1997, The Journal of urology.

[45]  G. Murphy,et al.  Carcinoma of prostate in men less than fifty years old. Data from American College of Surgeons' National Survey. , 1982, Urology.

[46]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[47]  A. Feinstein,et al.  A new clinical-anatomic staging system for evaluating prognosis and treatment of prostatic cancer. , 1986, Journal of chronic diseases.

[48]  M. Krousel‐Wood,et al.  Comparing comorbid-illness indices assessing outcome variation , 2007, Journal of General Internal Medicine.

[49]  R. Havlik,et al.  Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients , 1998, Cancer.

[50]  Kil,et al.  Comorbidity in patients with prostate cancer and its relevance to treatment choice , 1999, BJU international.

[51]  A. Partin,et al.  Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. , 1999, Urology.

[52]  C. Newschaffer,et al.  Comorbidity measurement in elderly female breast cancer patients with administrative and medical records data. , 1997, Journal of clinical epidemiology.

[53]  Michael Simoff,et al.  Impact of comorbidity on lung cancer survival , 2003, International journal of cancer.

[54]  S. Hall,et al.  The impact of comorbidity on the survival of patients with squamous cell carcinoma of the head and neck , 2000, Head & neck.

[55]  P. Warde,et al.  Does age influence the behaviour of localized prostate cancer? , 2001, BJU international.

[56]  Markus Graefen,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer - A multi-institutional update , 2004, Aktuelle Urologie.

[57]  A W Partin,et al.  Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. , 2000, The Journal of urology.

[58]  V. Nitti,et al.  Prevention and management of incontinence following radical prostatectomy. , 2001, The Urologic clinics of North America.

[59]  A. Glicksman,et al.  Low acute gastrointestinal and genitourinary toxicities in whole pelvic irradiation of prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[60]  D Gillatt,et al.  Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom , 1999, BMJ.

[61]  J. Piccirillo.  Inclusion of comorbidity in a staging system for head and neck cancer. , 1995, Oncology.

[62]  A. Renshaw,et al.  Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. , 2002, Urology.

[63]  J. Hanley,et al.  Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. , 1999, JAMA.

[64]  Michael J. Zelefsky,et al.  Comparison of the 5-Year Outcome and Morbidity of Three-Dimensional Conformal Radiotherapy Versus Transperineal Permanent Iodine-125 Implantation for Early-Stage Prostatic Cancer , 1999 .

[65]  J. Coebergh,et al.  Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. , 1999, Journal of clinical epidemiology.

[66]  P. Goldstraw,et al.  Hospital mortality and long-term survival after pulmonary resection in the elderly. , 1991, The Annals of thoracic surgery.

[67]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[68]  G GUIMARAES,et al.  Essential hypertension , 1950, Revue de medecine aeronautique.

[69]  A. Benghiat,et al.  Natural history and prognosis of prostate carcinoma in adolescents and men under 35 years of age. , 1992, British journal of urology.

[70]  K. Cummings,et al.  National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. , 1998, Urology.

[71]  D W Bates,et al.  Can comorbidity be measured by questionnaire rather than medical record review? , 1996, Medical care.

[72]  Ashesh B Jani,et al.  Early prostate cancer: clinical decision-making , 2003, The Lancet.

[73]  P. Walsh.  Predictive factors of urinary retention following prostate brachytherapy. , 2003, The Journal of urology.

[74]  D. Fryback,et al.  The impact of co-morbidity on life expectancy among men with localized prostate cancer. , 1996, The Journal of urology.